Chemomab Therapeutics (CMMB)
(Real Time Quote from BATS)
$1.13 USD
+0.01 (0.89%)
Updated Jul 22, 2024 11:04 AM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
CMMB 1.13 +0.01(0.89%)
Will CMMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMMB
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Other News for CMMB
Chemomab Therapeutics (CMMB) Gets a Buy from Roth MKM
Maxim Group Sticks to Its Buy Rating for Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab: Publications 'reinforce' potential of I CCL24 antibody for PSC
Chemomab Therapeutics management to meet virtually with Roth MKM